Tuxin Pharmaceutical (301089.SZ) released its first three quarters performance, with a net loss attributable to shareholders of RMB 40.9558 million.

Zhitong Finance APP News, Tuoxin Pharmaceutical (301089.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 323 million yuan, a year-on-year increase of 18.87%. Net loss attributable to shareholders of the listed company was 40.9558 million yuan. Net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 44.9349 million yuan.